Teva licenses Mersana cancer treatment for $334M - BusinessWeek

[INCIID News Feed]

<img alt="" height="1" width="1" />
Teva licenses Mersana cancer treatment for $334M
BusinessWeek
Mersana Therapeutics said Tuesday it licensed an experimental cancer drug to Teva Pharmaceutical Industries Ltd. in a deal that could be worth more than $334 million. Teva will handle development of the drug, designated XMT-1107, in all countries ...
Mersana signs $334M R&D deal with TevaMass High Tech
Mersana, Teva ink $334M deal for preclinical cancer drugFierceBiotech
Teva Gets Less GenericMotley Fool
Globes -BioWorld Online -PR Newswire (press release)
all 40 news articles &raquo;


More...